The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Induction of myelodysplasia by myeloid-derived suppressor cells
Open accessAbstract
Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDSCs are sufficient to create an MDS phenotype in murine experiments, and targeting them or their expansion leads to reconstitution of normal hematopoiesis.76,77”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationLanier, L. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,765
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. P. (2007) · Nature reviews. Immunology · doi:10.1038/nri2056 · Cited by 2,032
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationVogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · cited 2×
“Given our findings that S100A9 triggers CD33/Siglec 3 signaling and is involved in MDSC activation (17, 18, 37), we generated S100A9Tg mice to study MDSC-associated inflammation (37).”
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,278
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C. C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 907
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. L., Nacken, W. K. F., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 904
Self-citation
Research works printed but not linked: 3
- Kapanadze, 2013, J Hepatol., pii, S0168-8278(13)00421-2
- Xu, 2010, J Biomed Biotechnol., 2010, 105940
- Ioachim HL Medeiros LJ Cytopathology. In: Iochim’s Lymph Node Pathology. 4th ed. Philadelphia, Pennsylvania, USA: Wolters Kluwer/Lippincott Williams &Wilkins; 2008 21 22
Cited by
Sorted by citations
Items 201–300 of 316
Ichim, C. V., Dervovic, D., Chan, L. S. A., Robertson, C., Chesney, A. E., Reis, M. D., & Wells, R. A. (2018) · Biomarker Research · doi:10.1186/s40364-018-0149-4 · Cited by 11
Novel combinations to improve hematopoiesis in myelodysplastic syndrome
Syed, K. W., Naguib, S., Liu, Z., Cimmino, L., & Yang, F. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01647-1 · Cited by 12
Huang, H., Xu, Z., Gao, J., Li, B., Qin, T., Xu, Z., Ren, S., Zhang, Y., Jiao, M., Qu, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00349-4 · Cited by 11
Self-citationA Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome
Arellano-Ballestero, H., Sabry, M., & Lowdell, M. W. (2023) · Cells · doi:10.3390/cells12040633 · Cited by 14
Chrastinová, L., Pastva, O., Bocková, M., Lynn, N. S., Jr., Šácha, P., Hubálek, M., Suttnar, J., Kotlín, R., Štikarová, J., Hlaváčková, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49084-2 · Cited by 11
Stem Cells in the Myelodysplastic Syndromes
Zhan, D., & Park, C. Y. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.719010 · Cited by 12
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Kapoor, S., Champion, G., Basu, A., Mariampillai, A., & Olnes, M. J. (2021) · Cancers · doi:10.3390/cancers13195026 · Cited by 11
Expanding use of CD33-directed immunotherapy
Walter, R. B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1788540 · Cited by 11
Yang, Y., Abbas, S., Sayem, M. A., Dutta, A., & Mohi, G. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00947-y · Cited by 10
Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes
Xing, T., Yao, W., Zhao, H., Wang, J., Zhang, Y., Lv, M., Xu, L., Zhang, X., Huang, X., & Kong, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31129 · Cited by 10
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells
Cornelissen, L. A. M., Santegoets, K. C. M., Kers‐Rebel, E. D., Bossmann, S. A. J. F. H., ter Laan, M., Granado, D., & Adema, G. J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070953 · Cited by 10
Nian, S., Wang, K., Wang, J., Wang, S., Li, C., Li, N., & Chen, J. (2025) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2025.01.030 · Cited by 10
Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease
Hsieh, C., Chang, C., Hsu, Y., & Lin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113263 · Cited by 10
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
Comont, T., Treiner, E., & Vergez, F. (2021) · Diagnostics · doi:10.3390/diagnostics11111982 · Cited by 10
Přibyl, M., Hubáčková, S., Moudrá, A., Vančurová, M., Polackova, H., Stopka, T., Jonasova, A. T., Bokorová, R., Fuchs, O., Stritesky, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12768 · Cited by 10
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9
Sumi, S., Umemura, N., Takayama, E., Ohkoshi, E., Adachi, M., Mizuno‐Kamiya, M., Inagaki, T., Kawaki, H., Sumitomo, S., & Kondoh, N. (2017) · Oncology Reports · doi:10.3892/or.2017.5575 · Cited by 9
What is the role of the microenvironment in MDS?
Calvi, L. M., Li, A. J., & Becker, M. W. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101113 · Cited by 8
Dalton, R., Calescibetta, A. R., Zhou, J. M., Maurin, M. M., Ward, G., Trinh, T. L., Tu, N., Gilvary, D. L., Chen, X., Cheng, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031241 · Cited by 8
Self-citationKomrokji, R. S., Carraway, H. E., Germing, U., Wermke, M., Zeidan, A. M., Fu, E., Rüter, B. H., Burkard, U., Osswald, A., & Foran, J. M. (2022) · Haematologica · doi:10.3324/haematol.2021.280500 · Cited by 8
Uckun, F. M., & Watts, J. M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.757276 · Cited by 7
Regulation of prognosis-related Siglecs in the glioma microenvironment
Mao, R., Zhou, L., Yang, Y., Wang, P., Han, L., Zheng, J., Lv, G., & Zhou, D. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03762-9 · Cited by 7
Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells
D’Silva, S. Z., Rajadhyaksha, S. B., & Singh, M. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82101 · Cited by 7
Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis
de Matos, A. G., Magalhães, S. M. M., & Rauh, M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_608 · Cited by 7
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Tasis, A., Spyropoulos, T., & Mitroulis, I. (2025) · Cancers · doi:10.3390/cancers17050749 · Cited by 6
Alhajahjeh, A. A., Stahl, M. F., Kim, T. K., Kewan, T. Z., Stempel, J. M., Zeidan, A. M., & Bewersdorf, J. P. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2483855 · Cited by 6
Glass, J., Feng, X., Chen, J., Durrani, J., Wu, Z., Gao, S., Shalhoub, R. N., Wu, L., & Young, N. S. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf073 · Cited by 7
Wei, Y., Kanagal‐Shamanna, R., Zheng, H., Bao, N., Lockyer, P. P., Class, C. A., Darbaniyan, F., Lü, Y., Lin, K., Yang, H., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01605-1 · Cited by 6
Pathophysiology of Myelodysplastic Syndromes
Fontenay, M., Farhat, B., & Boussaid, I. (2021) · Hemato · doi:10.3390/hemato2030030 · Cited by 6
Putnam, C., Kondeti, L., Kesler, M. B. A., & Varney, M. E. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0374 · Cited by 6
Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
Götze, K. S. S., & Platzbecker, U. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000162 · Cited by 6
Bravo, G. M., Darbaniyan, F., Kanagal‐Shamanna, R., Gañán‐Gómez, I., Class, C. A., Sasaki, K., Naqvi, K., Wei, Y., Yang, H., Soltysiak, K. A., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106511 · Cited by 6
Munteanu, R. A., Gulei, D., Moldovan, C. S., Azzoni, E., Belver, L., Feder, R., Pîrv, S., Buzoianu, A. D., Einsele, H., Mittelman, M., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07861-0 · Cited by 5
Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy
Kapor, S., Radojković, M., & Santibanez, J. F. (2024) · Acta Histochemica · doi:10.1016/j.acthis.2024.152183 · Cited by 5
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman, D. A., & Davila, M. L. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.03.292 · Cited by 5
Xiao, N., He, X., Niu, H., Yu, H., Cui, N., Li, H., Li, Y., Shao, Z., Xing, L., & Wang, H. (2021) · Journal of Immunology Research · doi:10.1155/2021/4302515 · Cited by 5
Self-citationEmerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)
Mann, M., & Brunner, A. M. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100824 · Cited by 5
Tibbs, E. J., & Cao, X. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03162-z · Cited by 5
Zhou, T., Perez, S. N., Cheng, Z., Kinney, M. C., Lemieux, M. E., Scott, L. M., & Rebel, V. I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158649 · Cited by 5
Gibson, C. J., Ebert, B. L., & Steensma, D. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00060-3 · Cited by 5
Zheng, H., Zhao, P., Tan, Z., Yu, W., Werner, J., Stieglitz, E., Porter, C. C., Chandrakasan, S., Wechsler, D. S., Méndez‐Ferrer, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116087 · Cited by 4
Molecular Insights and Therapeutic Advances in Low-Risk Myelodysplastic Neoplasms: A Clinical Review
Dhillon, V., Maciejewski, J. P., & Balasubramanian, S. K. (2025) · Cancers · doi:10.3390/cancers17223610 · Cited by 4
Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates
Zhang, Y., Yan, L., Fan, C., Zhao, B., Chen, M., Hao, X., Zhu, G., Jia, Y., Xu, Y., & Shi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769944 · Cited by 4
Increased Circulating of CD54highCD181low Neutrophils in Myelodysplastic Syndrome
Yang, L., Li, H., Liu, Y., Xie, X., Zhang, H.-Q., Niu, H., Shao, Z., Xing, L., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585216 · Cited by 4
Self-citationMyelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 5
Immune checkpoint pathways: perspectives on myeloid malignancies
Rivera, G. A., Behbahan, I. S., & Greenberg, P. L. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1107554 · Cited by 4
Myeloid-Derived Suppressor Cells in Some Oncohematological Diseases
Ponomarev, А. V. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-1-29-38 · Cited by 4
Radujkovic, A., Boch, T., Nolte, F., Nowak, D., Kunz, C., Gieffers, A., Müller‐Tidow, C., Dreger, P., Hofmann, W., & Luft, T. (2020) · Cancers · doi:10.3390/cancers12123683 · Cited by 4
Chee, L. C. Y., Ritchie, D., Ludford‐Menting, M., Ripley, J., Chung, J., Park, D. J., Norton, S., Kenealy, M. K., & Koldej, R. M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13742 · Cited by 4
MDSC expansion during HIV infection: regulators, ART and immune reconstitution
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00272-9 · Cited by 4
Implications for metabolic disturbances in myelodysplastic syndromes
McGraw, K. L., & Larson, D. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.11.004 · Cited by 4
The role of innate immunity in MDS pathogenesis
Sallman, D. A., & List, A. F. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000217 · Cited by 4
Self-citationErythropoietin as an independent prognostic factor in myelodysplastic syndromes
Boyko, O., Simonova, M., Knysh, N., Danysh, O., Vygovska, Y., & Masliak, Z. (2021) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-43-no-1.15914 · Cited by 4
Garcia‐Manero, G., Gaddh, M., Platzbecker, U., Lindsley, R. C., Larson, S. M., Chevassut, T. J. T., Fenaux, P., Komrokji, R. S., Lyons, R. M., Al‐Kali, A., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06081-4 · Cited by 3
Arumugam, P., Heim, C. E., Fallet, R. W., Shinde, D., Thomas, V. C., Argüello, R. J., & Kielian, T. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117057 · Cited by 3
Li, X., Li, Q. Y., Xiang, X., Zhang, X., & Wu, Y. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156856 · Cited by 5
Wu, J., Liu, J., Chen, J., Yang, L., Li, F., Qin, T., Xu, Z., Liu, J., Zhou, J., Shi, L., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00664-1 · Cited by 3
Self-citationWang, Y., Xiao, X., Zheng, H., Bai, J. Y., Li, L., & Zhang, L. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2549519 · Cited by 3
Self-citationBID-ding on necroptosis in MDS
Croker, B. A., & Kelliher, M. A. (2019) · Blood · doi:10.1182/blood-2018-11-886242 · Cited by 3
Giagounidis, A. A. N. (2020) · Der Internist · doi:10.1007/s00108-019-00718-7 · Cited by 3
Guo, X., Yu, S., Ren, X., & Li, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19222 · Cited by 3
Niu, H., Zhang, M., Liu, M., Yang, L., Yang, L., Ren, J., Yu, Y., Liu, Y., Xing, L., Shao, Z., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3224 · Cited by 3
Self-citationCellular and immunotherapies for myelodysplastic syndromes
Stubbins, R. J., Cherniawsky, H. M., & Karsan, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.006 · Cited by 3
Myeloid-Derived Suppressor Cells in Aged Humans
Rauh, M. J., Cook, E. K., & Bowdish, D. M. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_96 · Cited by 3
Prise en charge des myélodysplasies
Duchmann, M., Fenaux, P., & Cluzeau, T. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.07.007 · Cited by 3
Chen, Y., Chan, K. C., Sin, C., Zheng, L., Wang, D., Tu, L., He, F., Hui, W. H. J., Leung, H. K., Ha, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017005 · Cited by 2
Wobus, M., Weidner, H., Wehner, R., Baumann, A.-L., Möbus, K., Balaian, E., Törngren, M., Vahtola, E., Eriksson, H., Winter, S., et al. (2026) · HemaSphere · doi:10.1002/hem3.70352 · Cited by 2
Sialic Acids and TAGs of Tumor Cells to Escape Immune Surveillance and Immune Editing
Kim, C. (2020) · Springer eBooks · doi:10.1007/978-981-15-5815-3_10 · Cited by 2
Morozova, E. V., Tcvetkov, N., Turtanova, I., & Moiseev, I. (2021) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2021-10-1-24-36 · Cited by 1
Bentivegna, S., Côme, C., Porse, B. T., Andersen, M. H., & Grønbæk, K. (2024) · British Journal of Haematology · doi:10.1111/bjh.19609 · Cited by 1
Accelerated senescence of bone marrow erythrocyte precursors in myelodysplastic syndrome
Liu, M., Yang, L., Liu, Y., Niu, H., Zhang, M., Shao, Z., Xing, L., & Wang, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2494676 · Cited by 1
Self-citationМеханизмы резистентности к иммунотерапии при MSI фенотипе
Федянин, М. Ю. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-15-3s1-11-30 · Cited by 1
Mina, A. A., Calvo, K. R., McKinnon, K. M., Raman, A. T., Wang, W., Cunningham, L., Liu, Y., Alexander, R., Larson, D. R., Pavletic, S. Z., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2661078 · Cited by 1
Vazquez, R., Deredec, N., Boussaid, I., Boncoeur, P., Knosp, C. A., Houvert, A., Zalmaï, L., Friedrich, C., Almire, C., Dussiau, C., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70504 · Cited by 1
Derosiers, N., Aguilar, W., Lewis, H.-G. S., MacDonald, M., & Posey, A. D. (2026) · Glycobiology · doi:10.1093/glycob/cwag035 · Cited by 1
Zhu, L., Liu, H., Zhang, S., fan, D., Yuan, X., Gao, X., & Nie, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218803 · Cited by 1
Under Pressure: When a Transformed Environment Pushes Cells to Malignancy
García-Fernández, M., & Méndez‐Ferrer, S. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.10.012 · Cited by 3
Physiopathologie des syndromes myélodysplasiques
Fontenay, M., Boussaid, I., & Chapuis, N. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.02.026 · Cited by 1
Marchand, V., Laplane, L., Valensi, L., Plo, I., Aglave, M., Silvin, A., Pasquier, F., Porteu, F., Vainchenker, W., Selimoglu‐Buet, D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111522 · Cited by 1
Recent Developments in Myelodysplastic Syndromes
Fuchs, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73936 · Cited by 1
Müller‐Thomas, C., Tüchler, H., Rudelius, M., Schneider, H., Pfefferkorn, S., & Götze, K. S. S. (2019) · Acta Haematologica · doi:10.1159/000496014 · Cited by 1
den Bergh, M. V., Shams, S. R., & Komrokji, R. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-44870-1_46-1 · Cited by 1
Wieboldt, R., Carlini, E., Lin, C., Börsch, A., Zingg, A., Lardinois, D., Herzig, P., Don, L., Zippelius, A., Laubli, H. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.29.547025 · Cited by 1
Gleason, M. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Syndromes myélodysplasiques et leucémies secondaires. Généralités, diagnostic et classification
Park, S., Cluzeau, T., Fenaux, P., & Dreyfus, F. (2014)
- Self-citation
[Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome].
Dong, P., Huang, L., & Sun, H. Y. (2017) · PubMed · doi:10.3760/cma.j.issn.0253-2727.2017.07.022
Myeloid-Derived Suppressor Cells in Aged Humans
Rauh, M. J., Cook, E. K., & Bowdish, D. M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_96-1
Myelodysplastic Syndromes: An Update on Pathophysiology and Management
Chai‐Ho, W., & Schiller, G. J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82166
Villaume, M. T., Ferrell, P. B., & Savona, M. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_4 · Cited by 1
Garcia‐Manero, G., Díez‐Campelo, M., Vellenga, E., Jacoby, M. A., Merchán, B., Breems, D. A., Cortelezzi, A., Doronin, V., de Soria, V. G.-G., Beckers, M., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26095
The Bone Marrow Microenvironment in Myelodysplastic Syndromes
Calvi, L. M., & Liesveld, J. L. (2019) · The Hematologist
den Bergh, M. V., Shams, S. R., & Komrokji, R. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_46
Shen, L., Sundstedt, A., Ciesielski, M. J., Miles, K. M., Celander, M., Adelaiye-Ogala, R. M., Orillion, A. R., Ciamporcero, E. S., Ramakrishnan, S., Ellis, L., et al. (2023) · doi:10.1158/2326-6066.c.6548818.v1
Data from Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
Tang, C.-H. A., Chang, S., Hashimoto, A., Chen, Y., Kang, C. W., Mato, A. R., Valle, J. R. D., Gabrilovich, D. I., & Hu, C. A. (2023) · doi:10.1158/2326-6066.c.6548944.v1
Self-citationData from Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
Tang, C.-H. A., Chang, S., Hashimoto, A., Chen, Y., Kang, C. W., Mato, A. R., Valle, J. R. D., Gabrilovich, D. I., & Hu, C. A. (2023) · doi:10.1158/2326-6066.c.6548944
Self-citationOßwald, L., Hamarsheh, S., Uhl, F. M., Andrieux, G., Klein, C., Dierks, C., Duquesne, S., Braun, L. M., Schmitt-Graeff, A. H., Duyster, J., et al. (2023) · doi:10.1158/1541-7786.c.6544992.v1
Myelodysplastic Syndrome Combined with Systemic Lupus Erythematosus: A Case Report
Fan, Q., & Guan, J. (2023) · Research in Health Science · doi:10.22158/rhs.v8n4p26
Metadata
- Authors
- Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., Youn, J.-I., Donatelli, S. S., Qin, D., De Witte, T., Tao, J., Wang, H., Cheng, P., Gabrilovich, D. I., List, A., & Wei, S.
- Affiliations
- Moffitt Cancer Center (US)
- Radboud University Medical Center (NL)
- University of South Florida (US)
- Corresponding author
- Wei, Sheng
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-10-15
- Volume
- 123
- Issue
- 11
- Pages
- 4595-4611
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3809779
- OpenAlex
- W2111063688
- Cited by
- 316
- References
- 63
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 19 · 2023: 28 · 2022: 31 · 2021: 43 · 2020: 30 · 2019: 26 · 2018: 23 · 2017: 25 · 2016: 30 · 2015: 17 · 2014: 9
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (AI056213)
- National Cancer Institute (T32CA115308, R01CA131076, R01CA100062, P30CA076292)
- National Institute of Allergy and Infectious Diseases (AI056213, R01AI056213)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- myelodysplastic syndrome, myeloid-derived suppressor cells, ineffective hematopoiesis, S100A9, CD33, immunoreceptor tyrosine-based inhibition motif, ITAM, DAP12, IL-10, TGF-beta, bone marrow, all-trans retinoic acid, transgenic mice
- MeSH terms
- Animals, Disease Models, Animal, Female, Hematopoiesis, HLA-DR Antigens, Humans, Ligands, Male, Mice, Transgenic, Myelodysplastic Syndromes, Signal Transduction, Mice, Knockout, Adoptive Transfer, Myeloid Cells, Calgranulin A, Calgranulin B, Mice, Cellular Microenvironment, Sialic Acid Binding Ig-like Lectin 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
